Anudeep B Pant, Yan Wang, Daniel W Mielcarz, Eli J Kasper, Kiel M Telesford, Megan Mishra, Azizul Haque, Jacqueline Y Channon, Lloyd H Kasper, Sakhina Begum-Haque
Journal of neuroimmunology 2017 Feb 15While examining the therapeutic value of anti-CD52 antibody against EAE/MS, we identified a unique subset of CD39+ Tregs in repopulating GALT tissues, a major lymphoid reservoir, which was accompanied by amelioration of disease. Furthermore, anti-CD52 treatment leads to increased expression of BDNF, IL-10, and SMAD3 in the brains of EAE mice. This condition is associated with suppression of IL-17, a critical inflammatory factor in EAE/MS progression. Additionally, we found elevated levels of CD4+CD39+ Tregs in PBMCs of RRMS patients treated with humanized anti-CD52 mAb. Thus, anti-CD52 can affect multiple immune mediated pathways involved in the pathogenesis of EAE/MS. Copyright © 2016. Published by Elsevier B.V.
Anudeep B Pant, Yan Wang, Daniel W Mielcarz, Eli J Kasper, Kiel M Telesford, Megan Mishra, Azizul Haque, Jacqueline Y Channon, Lloyd H Kasper, Sakhina Begum-Haque. Alteration of CD39+Foxp3+ CD4 T cell and cytokine levels in EAE/MS following anti-CD52 treatment. Journal of neuroimmunology. 2017 Feb 15;303:22-30
PMID: 28087077
View Full Text